Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.22% on an annualized basis producing an average annual return of 22.54%. Currently, Regeneron Pharmaceuticals ...

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...

A team from Logos Public Charter School won the state title for the fourth consecutive year and will advance to the international competition in Canada this summer, while a team from Eagle Point High ...

As you'd expect, this fresh version of the hit battle royale will arrive with an improved frame-rate (now 60FPS) and better resolution (2176x1224 when Switch 2 is docked, or 1600x900 undocked).

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo ® (cemiplimab) in patients with high-risk ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...

(Reuters) -Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly called "smoker's lung" failed a late-stage trial, although it ...

Jobs at Industry Leading Companies: Recent biochemistry graduates are employed at Ortho Clinical Diagnostics, St. Jude Children’s Research Hospital, ICON Laboratory, and Regeneron Pharmaceuticals, Inc ...

Welcome back to Week in Review! Tons of news from this week for you, including a hacking group that’s linked to the Spanish government; CEOs using AI avatars to deliver company earnings; Pocket ...

College of Land Science and Technology, State Key Laboratory of Efficient Utilization of Agricultural Water Resources, China Agricultural University, Beijing 100083, P. R. China ...